Gilead Sciences, Inc.
Close on Nov 3, 2026Market cap $207.66BP/E –Yield 1.89%
Gilead Sciences Arcus Biosciences by Year
Arcus Biosciences — Unbilled receivables / contract asset from Gilead ($M) ($M)
Gilead Sciences Arcus Biosciences: $11M in FY2025, down 45.0% from a year earlier.
Where the FY2025 figure comes from
Source: Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗
Reported in Arcus Biosciences (RCUS) Form 10-Q / 10-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Arcus Biosciences — Unbilled receivables / contract asset from Gilead ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11 | -45.0% | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗ |
| FY2024 | Dec 31, 2024 | 20 | -47.4% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 38 | -2.6% | Arcus Biosciences (RCUS) Form 10-K (filed 2025-02-25) ↗ |
| FY2022 | Dec 31, 2022 | 39 | -94.8% | Arcus Biosciences (RCUS) Form 10-K (filed 2024-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 745 | +67,627.3% | SEC Filing ↗ |
| FY2020 | Dec 31, 2020 | 1.10 | +1,000.0% | SEC Filing ↗ |
| FY2019 | Dec 31, 2019 | 0.10 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Gilead Sciences Arcus Biosciences ($M), annual FY2019–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus-contract-asset
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.
See a number that looks wrong?